Modern‐day cardio‐oncology: a report from the ‘Heart Failure and World Congress on Acute Heart Failure 2018’

Anker, Markus S.; Lena, Alessia; Hadzibegovic, Sara; Belenkov, Yury; Bergler‐Klein, Jutta; Boer, Rudolf A. de; Cohen‐Solal, Alain; Farmakis, Dimitrios; Haehling, Stephan von; López‐Fernández, Teresa; Pudil, Radek; Suter, Thomas M.; Tocchetti, Carlo G.; Lyon, Alexander R.

doi:10.1002/ehf2.12386

Cited by 22 publications

(14 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the industrialized nations the most common causes of death are cancer and cardiovascular (CV) disease . These diseases are associated on many different levels and patients frequently exhibit similar symptoms, such as dyspnoea, oedema, fatigue, weight loss and muscle wasting . They also share similar risk factors, such as tobacco smoking, diabetes, obesity and hypertension .…”

Section: Introductionmentioning

confidence: 99%

Increased resting heart rate and prognosis in treatment‐naïve unselected cancer patients: results from a prospective observational study

Anker

Frey

Goliasch

et al. 2020

European J of Heart Fail

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Increased resting heart rate and prognosis in treatment‐naïve unselected cancer patients: results from a prospective observational study

Anker

Frey

Goliasch

et al. 2020

European J of Heart Fail

Self Cite

View full text Add to dashboard Cite

show abstract

“…Cardiotoxicity can be caused by cytotoxic chemotherapy, radiotherapy, molecular targeted therapies, and immunemodulating agents. At present, the cardio-oncology researches mainly focus on pathophysiological mechanisms in the development of heart failure, risk factors, and early signs of cardiotoxicity detectable, as well as cardioprotective treatments [17].…”

Section: Discussionmentioning

confidence: 99%

Bibliometric Analysis of the Results of Cardio‐Oncology Research

Wei

Liao

Chang

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To analyze the development of cardio-oncology, summarize the research achievements, and provide proposals for its future research. Methods. The web of science database was used to search for “cardio-oncology” and “oncocardiology” related articles from the beginning of the database (1970) to April 5, 2019. Excel 2016 and Cytoscape were used to analyze the trend of cardio-oncology research. Results. A total of 356 articles were obtained. The number of articles has grown rapidly in recent years. Cardiac injury caused by tumor therapy was a research hotspot (n = 107). Researchers paid more attention to the prevention and treatment of cardiotoxicity (n = 54). Experimental researches were a small part of all studies (n = 72), mainly focusing on the study of cancer drugs’ cardiac injury, test indicators of cardiotoxicity, and preventive drugs. The United States (n = 156.25), Italy (n = 48.5), and Canada (n = 23.5) published the most articles, making a great contribution to the development of cardio-oncology. Conclusions. Cardio-oncology has been developing rapidly and receiving a large amount of research efforts in recent years. Most articles on cardio-oncology were published by the authors from the United States (44%) and Italy (17%), while other countries need to pay more attention to cardio-oncology. As an independent discipline, cardio-oncology is certainly in need of significant progress, but it has formed a basic framework, which has obtained many leading theories and meaningful achievements in diagnostic criteria, diagnostic methods, prevention and treatment, mechanism research, and influencing factor. Cardiac injury of tumor drugs has always been a research hotspot in this discipline, and there is still a lot of research space. The research about detection methods of cardiotoxicity and preventive drugs is gradually increasing. Basic research lags behind, and many mechanisms are still unclear.

show abstract

“…There is a complex and intriguing relationship between HF and cancer 70,84–87 . On one hand, patients with HF have a higher occurrence of malignancy due to a combination of underlying shared mechanisms and risk factors 58,59,88 .…”

Section: Heart Failure and Cancermentioning

confidence: 99%

Heart failure in the last year: progress and perspective

et al. 2020

Self Cite

View full text Add to dashboard Cite

Research about heart failure (HF) has made major progress in the last years. We give here an update on the most recent findings. Landmark trials have established new treatments for HF with reduced ejection fraction. Sacubitril/valsartan was superior to enalapril in PARADIGM‐HF trial, and its initiation during hospitalization for acute HF or early after discharge can now be considered. More recently, new therapeutic pathways have been developed. In the DAPA‐HF and EMPEROR‐Reduced trials, dapagliflozin and empagliflozin reduced the risk of the primary composite endpoint, compared with placebo [hazard ratio (HR) 0.74; 95% confidence interval (CI) 0.65–0.85; P < 0.001 and HR 0.75; 95% CI 0.65–0.86; P < 0.001, respectively]. Second, vericiguat, an oral soluble guanylate cyclase stimulator, reduced the composite endpoint of cardiovascular death or HF hospitalization vs. placebo (HR 0.90; 95% CI 0.82–0.98; P = 0.02). On the other hand, both the diagnosis and treatment of HF with preserved ejection fraction, as well as management of advanced HF and acute HF, remain challenging. A better phenotyping of patients with HF would be helpful for prognostic stratification and treatment selection. Further aspects, such as the use of devices, treatment of arrhythmias, and percutaneous treatment of valvular heart disease in patients with HF, are also discussed and reviewed in this article.

show abstract

Modern‐day cardio‐oncology: a report from the ‘Heart Failure and World Congress on Acute Heart Failure 2018’

Cited by 22 publications

References 101 publications

Increased resting heart rate and prognosis in treatment‐naïve unselected cancer patients: results from a prospective observational study

Increased resting heart rate and prognosis in treatment‐naïve unselected cancer patients: results from a prospective observational study

Bibliometric Analysis of the Results of Cardio‐Oncology Research

Heart failure in the last year: progress and perspective

Contact Info

Product

Resources

About